Five attractions
-
Industry Leader
-
global
-
Specialist
Group -
Advancement of women's participation in society
-
Challenger
Industry Leader
We are a leading company in the industry for non-clinical trial contracting.
SNBL was established in Kagoshima in 1957 as the first contract research institute for drug development in the Japan. For more than 60 years since then, we have built a solid business foundation in the preclinical study contract business.
Going forward, theSNBL Group will continue to provide one-of-a-kind business value and meet the expectations of all stakeholders.
SNBL Trust & Track Records
global
From Japan to the World
Taking on the challenge of becoming a global company
As a contract research organization providing essential safety and efficacy test data in the pharmaceutical development process, we have been thriving for over half a century.
During this time, as we accumulated achievements, the SNBL Group has expanded its business globally in Japan, the USA, China, and Cambodia, establishing a consistent service system for research contracting in the medical field. Leveraging this comprehensive strength, we now meet all drug discovery needs of clients worldwide and provide prompt and accurate services in all areas of medical research and development, from basic research to late-stage clinical trials.
Global business initiatives
Currently, we have established facilities in SNBL CHINA and SNBL CAMBODIA.
Additionally, we have received a full accreditation notification from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).
Going forward, our group intends to maintain high ethical standards regarding animal welfare, conduct proper experiments and breeding management, and consider the occupational safety and health of those involved in experiments, striving to remain a world-class facility.
Human resource foundation for global trials
In addition to having personnel of various nationalities, we have many who have worked at overseas bases, enabling us to handle a wide range of trials from international clients.
Furthermore, we can be directly or indirectly involved in trials from international clients, and the ability to work across nationalities using English is one of our company's attractions. We support the growth of a wide range of personnel who can thrive globally, not only through domestic contract trials but also through contract trials from international clients.
Specialist Group
We are a group of specialists with expertise and skills.
In our company, starting with the CEO who is a physician, doctors are placed in key positions. Additionally, numerous medical specialists such as veterinarians, nurses, pharmacists, and clinical laboratory technicians are entrusted with their responsibilities in appropriate placements. We believe that solid knowledge, skilled techniques, and abundant experience, and the trust based on these experiences, are the foundational strength supporting the development of our business.
Specialists who acquired knowledge, skills, and qualifications in the USA
At the U.S. preclinical business company (SNBL U.S.A., Ltd.), many employees have been seconded from the domestic safety research institute (Kagoshima) and the drug metabolism analysis center (Wakayama), and have spent several years living locally while engaging in preclinical trials. In addition, the expertise of U.S. employees is extensive, covering both in vivo and in vitro, and employees with rich specialized knowledge continue to hone their skills even after returning to Japan. Regardless of language barriers, the skills, knowledge, and qualifications they acquired in the U.S. are invaluable experiences and precious assets. Moreover, it is rare to find a company with so many U.S.-based employees, and it goes without saying that the skills, knowledge, and qualifications cultivated in the U.S. have been sublimated into our company's wisdom.
Number of SNBL qualified students
Advancement of women's participation in society
First in Kagoshima Prefecture! Acquired the 2018 Advanced Company Where Women Shine Award
Our company has recently received the Prime Minister's Award in the 2018 Advanced Company Where Women Shine Awards, organized by the Gender Equality Bureau of the Cabinet Office.
The Advanced Company Where Women Shine Awards recognize companies with outstanding achievements in promoting policies, initiatives, and results related to the appointment of women to executive and managerial positions, as well as in the disclosure of such information, with the aim of contributing to the realization of a society where women shine. Our company is the first recipient of this award in Kagoshima Prefecture.
|
Award Remarks and Introduction of Initiatives |
473KB |
First in Kagoshima Prefecture! Obtained the highest rating in the Eruboshi certification system based on the Act on Promotion of Women's Participation and Advancement in the Workplace
On September 30, our company obtained the highest rating, 'Eruboshi Level 3,' in the certification system by the Minister of Health, Labour and Welfare based on the Act on Promotion of Women's Participation and Advancement in the Workplace.
This certification system, based on the Act on Promotion of Women's Participation and Advancement in the Workplace enacted on April 1, 2016, recognizes companies with excellent implementation of initiatives related to promoting women's participation. The term 'Eruboshi' embodies a cheer for women and a wish for more shining women to emerge. Our company is the first in Kagoshima Prefecture to obtain this certification.
This is a system where the director of the labor bureau in each prefecture certifies companies that have formulated and achieved action plans related to improving employment environments based on the Act on Advancement of Measures to Support Raising Next-Generation Children.
Our company formulated and achieved an action plan from April 2005 to March 2009 and was certified by the director of the Kagoshima Labor Bureau on May 11, 2009.
New Japan Nursery ☆Sparkle☆
In December 2007, with the desire to improve the situation where women are forced to resign due to marriage or childbirth, we established an on-site nursery.
Currently, toddlers are energetically playing at the nursery near the workplace.
Seen from a female employee's point of viewSNBL
To determine what is necessary for women to fully demonstrate their abilities in the workplace, we established the 'Working Nadeshiko Committee' in July 2014. This committee promotes initiatives for women's participation and has implemented specific systems based on its opinions, such as a childcare fee subsidy system and a half-day paid leave system (currently every two hours).
Additionally, as follow-up after appointing to managerial positions, we conduct regular interviews with division heads and department heads, establishing a support system that allows managerial staff to fully utilize their abilities.
As a result, the ratio of female managers increased to 24.6% in 2018, and in 2017, our company's first female executive was appointed.
Furthermore, the ratio of female hires continues to increase, reaching 56.7% in 2018.
Challenger
We are a challenger who opens up new fields. AtSNBL , we are engaged in the translational research (TR) business through pharmaceutical research and development, bridging the gap from basic research to clinical research. In addition, we believe that continuing to be a company that values the environment, life, and human resources is the essential raison d'être of the company, and we are taking on the challenge of expanding our business in a wide range of ways.
Translational Research (TR) Business
Satsuma Corporation was established by our company to develop an intranasal migraine medication (dihydroergotamine) in the United States, and we have licensed out the application of our intranasal delivery platform technology to dihydroergotamine.
Subsequently, after evaluation by major U.S. investment firms (RA Capital Management, LLC and TPG Biotechnology Partners V.L.P.), we successfully raised a total of $12 million in development funding in December 2016.
Satsuma Corporation plans to generate revenue through licensing out to pharmaceutical companies or joint ownership through partial stock sales, following the acquisition of Proof-of-Concept through clinical trials of the intranasal dihydroergotamine.
Diverse business expansion
Stable supply of eels
Due to the poor catch of glass eels in recent years, the eel farming industry is facing a critical situation for its survival, and additionally, the opacity of eel distribution is being socially criticized.
Due to various circumstances and the overfishing of natural glass eels, the resources of the Japanese eel have drastically decreased, and the International Union for Conservation of Nature (IUCN) has designated the Japanese eel as an 'endangered species.' Therefore, there is a strong desire to establish mass production technology using artificial seedlings.
In response, our company established an eel seedling production research department in 2014 and is working to create a business system that can stably supply glass eels, in collaboration with local eel farming industries, to maintain and develop domestic eel production. In 2017, we succeeded for the first time in the world in producing artificial seedlings of Japanese eel using a 'closed-loop circulation system' developed independently in inland areas.
